Skip to main content
Clinical Trials/NCT00813553
NCT00813553CompletedNot Applicable

Effect of Two 8-week β-alanine Supplementation Protocols on Muscle Carnosine

Société des Produits Nestlé (SPN)2 sites in 1 country30 target enrollmentStarted: December 1, 2008Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
30
Locations
2
Primary Endpoint
muscle carnosine concentration

Study Overview

Brief Summary

Carnosine is a natural acid buffering substance of muscle. The primary objective of this study is to test whether a nutritional supplement of beta-alanine enhances carnosine content in muscle.

Detailed Description

Volunteers will be randomized to receiving 3 nutritional supplements. Two supplements contain beta-alanine at different doses, the third supplement is a placebo.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 40 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Stable health as evaluated by medical evaluation
  • Body mass index higher than 18 kg/m2
  • Body mass index lower than 25 kg/m2, unless body fat is less than 20%

Exclusion Criteria

  • intolerance to β-alanine,
  • allergy to soy, fish and crustacean
  • participation in another intervention study
  • consumer of dietary supplement susceptible to contain beta-alanine
  • determined to have very high baseline muscle carnosine concentration

Outcomes

Primary Outcomes

muscle carnosine concentration

Time Frame: 0 to 8 weeks

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Société des Produits Nestlé (SPN)
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials